Evidence map›Paper›PMID 33106178›Full record

ArticleGenome biology2020

RNA editing in cancer impacts mRNA abundance in immune response pathways.

Tracey W Chan, Ting Fu, Jae Hoon Bahn, Hyun-Ik Jun, Jae-Hyung Lee, Giovanni Quinones-Valdez, Chonghui Cheng, Xinshu Xiao

Open access · goldAbstract read
In one paragraph

Article in Genome biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Lactobacillus for ribosome peptide editing cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. DNA and RNA Binding Proteins: From Motifs to Roles in Cancer.International journal of molecular sciences · 2022
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Tracey W ChanBioinformatics Interdepartmental Program, UCLA, Los Angeles, CA, USA.
Ting FuMolecular, Cellular and Integrative Physiology Interdepartmental Program, UCLA, Los Angeles, CA, USA.
Jae Hoon BahnDepartment of Integrative Biology and Physiology, UCLA, Los Angeles, CA, USA.
Hyun-Ik JunDepartment of Integrative Biology and Physiology, UCLA, Los Angeles, CA, USA.
Jae-Hyung LeeDepartment of Integrative Biology and Physiology, UCLA, Los Angeles, CA, USA.
Giovanni Quinones-ValdezDepartment of Bioengineering, UCLA, Los Angeles, CA, USA.
Chonghui ChengLester & Sue Smith Breast Center & Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Xinshu XiaoBioinformatics Interdepartmental Program, UCLA, Los Angeles, CA, USA. gxxiao@ucla.edu.ORCID 0000-0002-9362-8029
University of California, Los Angeles · USBaylor College of Medicine · USLa Jolla Bioengineering Institute · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Regulation of alternative splicing during epithelial-mesenchymal transitionR35GM131876 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI Chonghui Cheng · 2019 to 2026
$3.9M
Analysis of functional genetic variants in RNA processing and expressionU01HG009417 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI XIAO, XINSHU GRACE · 2017 to 2021
$3.2M
Prioritization of splicing-altering genetic variants in Alzheimer's diseaseR01AG056476 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI XIAO, XINSHU GRACE · 2017 to 2021
$2.0M
Biomedical Big Data Training GrantT32LM012424 · NLM · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PELLEGRINI, MATTEO · 2016 to 2019
$1.0M
National Human Genome Research Institute (US) U01HG009417NCI NIH HHS P30 CA016042NIA NIH HHS R01 AG056476NIA NIH HHS R01AG056476NIGMS NIH HHS R35 GM131876NIGMS NIH HHS R35GM131876NLM NIH HHS T32 LM012424
6 · The paper itself

Abstract

backgroundRNA editing generates modifications to the RNA sequences, thereby increasing protein diversity and shaping various layers of gene regulation. Recent studies have revealed global shifts in editing levels across many cancer types, as well as a few specific mechanisms implicating individual sites in tumorigenesis or metastasis. However, most tumor-associated sites, predominantly in noncoding regions, have unknown functional relevance.

resultsHere, we carry out integrative analysis of RNA editing profiles between epithelial and mesenchymal tumors, since epithelial-mesenchymal transition is a key paradigm for metastasis. We identify distinct editing patterns between epithelial and mesenchymal tumors in seven cancer types using TCGA data, an observation further supported by single-cell RNA sequencing data and ADAR perturbation experiments in cell culture. Through computational analyses and experimental validations, we show that differential editing sites between epithelial and mesenchymal phenotypes function by regulating mRNA abundance of their respective genes. Our analysis of RNA-binding proteins reveals ILF3 as a potential regulator of this process, supported by experimental validations. Consistent with the known roles of ILF3 in immune response, epithelial-mesenchymal differential editing sites are enriched in genes involved in immune and viral processes. The strongest target of editing-dependent ILF3 regulation is the transcript encoding PKR, a crucial player in immune and viral response.

conclusionsOur study reports widespread differences in RNA editing between epithelial and mesenchymal tumors and a novel mechanism of editing-dependent regulation of mRNA abundance. It reveals the broad impact of RNA editing in cancer and its relevance to cancer-related immune pathways.

Indexed as

ImmunityRNA EditingA549 CellsAdenosine DeaminaseCarcinogenesisCell Line, TumorGene Expression RegulationGene Knockdown TechniquesHumansNeoplasmsNuclear Factor 90 ProteinsRNA-Binding ProteinsRNA, MessengerSequence Analysis, RNAADARB1 protein, humanADAR protein, humanAdenosine DeaminaseILF3 protein, humanNuclear Factor 90 ProteinsRNA-Binding ProteinsRNA, Messenger

Identifiers

PMID33106178
PMCPMC7586670
OpenAlexW3093713985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.